A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
At a glance
- Drugs PF 06865571 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 21 May 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Planned End Date changed from 11 Apr 2018 to 30 May 2018.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.